MSN による配信5 日
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) ...
Nasdaq7 日
Larimar Therapeutics Begins Dosing Adolescents in Pediatric Study for Friedreich's Ataxia
Larimar Therapeutics has initiated dosing for adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for nomlabofusp, a potential treatment for Friedreich’s ataxia.
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric ...
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the ...
Morningstar7 日
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric ...
“Dosing adolescents is the first step in evaluating the safety and PK of nomlabofusp in pediatric patients with FA. We continue to enroll adolescents in our first cohort. This cohort will be ...
manilatimes6 日
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ...